Rhythm Pharmaceuticals (RYTM) Gets a Hold Rating from Morgan Stanley

In a report released today, Jeffrey Hung from Morgan Stanley maintained a Hold rating on Rhythm Pharmaceuticals (RYTMResearch Report), with a price target of $8.00. The company’s shares closed last Friday at $8.95.

According to, Hung is a 5-star analyst with an average return of 23.5% and a 56.7% success rate. Hung covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Ultragenyx Pharmaceutical, and ACADIA Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Rhythm Pharmaceuticals with a $15.50 average price target, implying an 89.7% upside from current levels. In a report issued on July 12, Goldman Sachs also maintained a Hold rating on the stock with a $6.00 price target.

See the top stocks recommended by analysts >>

Rhythm Pharmaceuticals’ market cap is currently $405.7M and has a P/E ratio of -2.65.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Rhythm Pharmaceuticals, Inc. develops and commercializes peptide therapeutics for the treatment of gastrointestinal diseases and genetic deficiencies. It focuses on the treatment for Prader-Willi Syndrome and Pro-Opiomelanocortin deficiency obesity. The firm rapidly develops setmelanotide for rare genetic disorders of obesity caused by MC4 pathway deficiencies and provides advance setmelanotide for POMC deficiency obesity and LEPR deficiency obesity as first indications in upstream MC4 pathway deficiencies. The company was founded by Bart Henderson in February 2010 and is headquartered in Boston, MA.

Read More on RYTM:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More